Michael Gilman joined SV in 2026 and is currently an Operating Partner.
Michael Gilman is currently Chairman of the Board of Arrakis Therapeutics, a privately held biopharmaceutical company developing small-molecule medicines targeting RNA. Dr. Gilman also serves on the board of directors of Scholar Rock (NASDAQ:SRRK).
He previously spent ten years as Chief Executive Officer of Arrakis. He also served as Chief Executive Officer of Obsidian Therapeutics (NASDAQ:OBX), a developer of regulated cell therapies; Padlock Therapeutics, a developer of drugs for autoimmune disease, acquired in 2016 by Bristol-Myers Squibb; and Stromedix, which developed an antibody medicine for pulmonary fibrosis, acquired by Biogen in 2012.
Prior to founding Stromedix, Dr. Gilman was Executive Vice President of Research at Biogen and Executive Vice President and Chief Scientific Officer at ARIAD Pharmaceuticals.
From 1986 to 1994, Dr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation.
Academic Credentials
Dr. Gilman earned an SB in Life Sciences from MIT and a PhD in Biochemistry from University of California, Berkeley. He was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute.
